Navigation Links
MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
Date:6/5/2008

WARREN, N.J. and PORTAGE, Ind., June 5 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today the appointment of Vincent Viviani as Senior Vice President, Manufacturing and Operations. Mr. Viviani will report to A. Mark Schobel, President and CEO and join the Company's executive management team.

Mr. Schobel commented, "Vince is a significant addition to the MonoSol Rx executive team. His leadership and experience will be instrumental as we look to further enhance the productivity and operational efficiency of our recently expanded manufacturing facilities. Since bringing our second manufacturing facility online, we have tripled our production capacity to more than three billion strips annually. This additional capacity will help us to meet the growing demand for our thin film drug delivery technology in both the consumer and prescription drug markets."

Mr. Viviani joins MonoSol Rx after leading his own consulting firm from 2006 to 2008. As President of Viviani Consulting, Mr. Viviani specialized in helping small and medium-sized businesses develop strategies to bolster profitability, operational functionality and business process management. Prior to his consulting work, Mr. Viviani was Vice President, Quality Systems for Playtex Products, Inc. where he developed and led corporate-wide quality systems. Earlier in his career, Mr. Viviani held various manufacturing and operations positions with Reckitt & Colman and was Director of Distribution and Logistics for Lechters, Inc.

About MonoSol Rx

MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company's thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. MonoSol Rx's
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
2. Flashpoint Launches Flashlight Interactive, Names Kristen Goelz Head of New Division
3. Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss
4. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
5. NJHA Names Fred J. Jacobs General Counsel
6. AMA Foundation Names Minority Scholars Award Recipients
7. The Gladney Center for Adoption Names Mark L. Melson as Executive Vice President/Chief Development Officer
8. Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans
9. North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year
10. Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy
11. Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 2Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 3Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 4Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 5Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 6Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 7Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 8Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 9Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:Virus evolution topic of Darwin talk at UH April 2 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 2Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 4Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 5Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 6Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 7Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 8Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 9Health News:National Council on Disability Calls for New Federal Approach to Disability Policy 2
Other Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32